Latest Conference Articles

November 7th 2024, 7:30pm

SITC Meeting

Radiomic biomarkers can predict treatment response through assessments of tumor growth in patients with metastatic uveal melanoma treated with roginolisib.

November 7th 2024, 6:10pm

SITC Meeting

The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.

November 7th 2024, 3:59pm

OncLive co-hosts Kristie L. Kahl and Andrew Svonavec talk to program co-chair Benjamin P. Levy, MD, to highlight what to expect in the latest oncology developments from the 42nd Annual Chemotherapy Foundation Symposium to be held in New York City.

November 1st 2024, 7:00pm

EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Casdatifan was well tolerated and had durable clinical activity in patients with metastatic clear cell renal cell carcinoma.

October 29th 2024, 4:46pm

EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

IDE397 is the first MAT2A inhibitor to show clinical activity and safety in patients with MTAP-deletion urothelial cancer and non–small cell lung cancer.

October 28th 2024, 7:55pm

EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

The first-in-class CDK8/19 inhibitor RVU120 demonstrated early signs of clinical activity in patients with relapsed/refractory metastatic or advanced solid tumors.

October 28th 2024, 5:28pm

EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

RMC-9805 was proven safe and active in patients with previously treated, KRAS G12D–mutant pancreatic ductal adenocarcinoma.

October 25th 2024, 8:00pm

Treatment with APR-1051 appears safe and well tolerated in patients with advanced solid tumors and select cancer-associated gene alterations.

October 25th 2024, 4:03pm

TYRA-300 was safe and produced antitumor activity in metastatic urothelial cancer harboring FGFR3 alterations.

October 17th 2024, 12:00pm

ESMO Congress

Oncology experts share notable clinical trials and up-and-coming therapies presented at the 2024 ESMO Congress.

October 11th 2024, 1:01pm

MR-Linac adaptive radiotherapy plus temozolomide reduces CTV margins in high-grade glioma, according to results from the phase 2 UNITED trial.

October 9th 2024, 1:00pm

ASTRO Annual Meeting

Patients with WHO grade II/III recurrent meningioma experienced clinically meaningful efficacy with 177Lutetium-Dotatate.

October 8th 2024, 6:53pm

ASTRO Annual Meeting

The combination of nivolumab plus radiotherapy reduces rates of biochemical recurrence in gleason grade 5 prostate cancer.

October 6th 2024, 10:00am

Atezolizumab administered concurrently with chemoradiation failed to improve OS and PFS outcomes compared with standard chemoradiation alone in LS-SCLC.

October 2nd 2024, 10:52pm

International Myeloma Society Annual Meeting

MRD negativity was sustained at 1 year following the cessation of maintenance lenalidomide in multiple myeloma.

October 2nd 2024, 8:06pm

International Myeloma Society Annual Meeting

The second-generation, BCMA-directed CAR T-cell therapy HBI0101 led to an objective response rate of 92% in patients with relapsed/refractory multiple myeloma.

October 2nd 2024, 7:30pm

International Myeloma Society Annual Meeting

Binod Dhakal, MD, discusses survival data with ciltacabtagene autoleucel in lenalidomide-refractory relapsed/refractory multiple myeloma.

October 2nd 2024, 7:30pm

International Myeloma Society Annual Meeting

Jill Corre, PharmD, PhD, discusses minimal residual disease negativity rates after treatment with D-VTd induction/consolidation in newly diagnosed multiple myeloma.

October 2nd 2024, 7:29pm

International Myeloma Society Annual Meeting

No significant differences in patient-reported outcomes were observed with BPd vs PVd among patients with relapsed/refractory multiple myeloma.

October 2nd 2024, 1:02pm

International Myeloma Society Annual Meeting

The BCMA-targeting ADC HDP-101 demonstrated early efficacy and manageable toxicity in relapsed/refractory multiple myeloma.